---
title: "Adagene Inc. (ADAG.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ADAG.US.md"
symbol: "ADAG.US"
name: "Adagene Inc."
industry: "Biotechnology"
datetime: "2026-05-02T11:01:00.260Z"
locales:
  - [en](https://longbridge.com/en/quote/ADAG.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ADAG.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ADAG.US.md)
---

# Adagene Inc. (ADAG.US)

## Company Overview

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.adagene.com](https://www.adagene.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-02T04:30:19.000Z

**Overall: C (0.46)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 153 / 387 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 7332.76% |  |
| Net Profit YoY | 47.32% |  |
| P/B Ratio | 7.14 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 252397309.08 |  |
| Revenue | 7670902.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -41.01% | E |
| Profit Margin | -229.56% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 7332.76% | A |
| Net Profit YoY | 47.32% | B |
| Total Assets YoY | -12.33% | E |
| Net Assets YoY | 2.72% | C |
| Cash Flow Margin | 88.92% | C |
| OCF YoY | 7332.76% | A |
| Turnover | 0.09 | E |
| Gearing Ratio | 33.69% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Adagene Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "7332.76%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "47.32%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "7.14",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "252397309.08",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "7670902.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-41.01%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-229.56%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "7332.76%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "47.32%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.33%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.72%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "88.92%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "7332.76%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.09",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "33.69%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -14.33 | 467/387 | - | - | - |
| PB | 7.14 | 354/387 | 3.69 | 2.36 | 1.82 |
| PS (TTM) | 32.90 | 223/387 | 1091.47 | 885.55 | 799.19 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 02 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 03 | OpGen (OPGN.US) | B | A | A | A | C | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Argenx (ARGX.US) | A | A | B | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-27T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 83% |
| Hold | 1 | 17% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.82 |
| Highest Target | 14.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ADAG.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ADAG.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ADAG.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ADAG.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**